Follow
Pr Michel Obeid MD PhD
Pr Michel Obeid MD PhD
Verified email at chuv.ch
Title
Cited by
Cited by
Year
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
L Apetoh, F Ghiringhelli, A Tesniere, M Obeid, C Ortiz, A Criollo, G Mignot, ...
Nature medicine 13 (9), 1050-1059, 2007
33282007
Calreticulin exposure dictates the immunogenicity of cancer cell death
M Obeid, A Tesniere, F Ghiringhelli, GM Fimia, L Apetoh, JL Perfettini, ...
Nature medicine 13 (1), 54-61, 2007
32012007
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares, MO Pequignot, A Tesniere, F Ghiringhelli, S Roux, N Chaput, ...
The Journal of experimental medicine 202 (12), 1691-1701, 2005
15542005
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
F Martins, L Sofiya, GP Sykiotis, F Lamine, M Maillard, M Fraga, ...
Nature reviews Clinical oncology 16 (9), 563-580, 2019
14892019
Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis
M Obeid, T Panaretakis, N Joza, R Tufi, A Tesniere, P Van Endert, ...
Cell Death & Differentiation 14 (10), 1848-1850, 2007
5542007
Ecto‐calreticulin in immunogenic chemotherapy
M Obeid, A Tesniere, T Panaretakis, R Tufi, N Joza, P Van Endert, ...
Immunological reviews 220 (1), 22-34, 2007
2522007
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
J Haanen, M Obeid, L Spain, F Carbonnel, Y Wang, C Robert, AR Lyon, ...
Annals of Oncology 33 (12), 1217-1238, 2022
2472022
Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from “silent” to immunogenic
M Obeid, T Panaretakis, A Tesniere, N Joza, R Tufi, L Apetoh, ...
Cancer research 67 (17), 7941-7944, 2007
2012007
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
F Martins, GP Sykiotis, M Maillard, M Fraga, C Ribi, T Kuntzer, O Michielin, ...
The Lancet Oncology 20 (1), e54-e64, 2019
1732019
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J Haanen, MS Ernstoff, Y Wang, AM Menzies, I Puzanov, P Grivas, ...
Annals of Oncology 31 (6), 724-744, 2020
1562020
ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin
M Obeid
The journal of Immunology 181 (4), 2533-2543, 2008
1362008
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
J Haanen, M Ernstoff, Y Wang, A Menzies, I Puzanov, P Grivas, J Larkin, ...
Journal for immunotherapy of cancer 8 (1), 2020
1112020
Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference
N Chaput, S De Botton, M Obeid, L Apetoh, F Ghiringhelli, T Panaretakis, ...
Journal of molecular medicine 85, 1069-1076, 2007
1002007
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy
E Ghisoni, A Wicky, H Bouchaab, M Imbimbo, J Delyon, BG Moura, ...
European Journal of Cancer 149, 153-164, 2021
952021
Reactivation of IgA vasculitis after COVID-19 vaccination
M Obeid, C Fenwick, G Pantaleo
The Lancet Rheumatology 3 (9), e617, 2021
732021
COVID-19 and lung cancer: risks, mechanisms and treatment interactions
A Addeo, M Obeid, A Friedlaender
Journal for immunotherapy of cancer 8 (1), 2020
712020
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
A Horisberger, S La Rosa, JP Zurcher, S Zimmermann, F Spertini, ...
Journal for immunotherapy of cancer 6, 1-7, 2018
592018
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
F Zou, D Faleck, A Thomas, J Harris, D Satish, X Wang, A Charabaty, ...
Journal for immunotherapy of cancer 9 (11), 2021
572021
Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients
M Obeid, M Suffiotti, C Pellaton, H Bouchaab, A Cairoli, V Salvadé, ...
JAMA oncology 8 (5), e220446-e220446, 2022
522022
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
J Doms, JO Prior, S Peters, M Obeid
Annals of Oncology 31 (9), 1273-1275, 2020
462020
The system can't perform the operation now. Try again later.
Articles 1–20